WALTHAM, MA, Xilio Therapeutics has closed a $95 million Series C financing led by Rock Springs Capital.
Xilio Therapeutics, a biotechnology company developing immunotherapies for patients with cancer, has closed a $95 million Series C financing.
The financing was led by Rock Springs Capital and was joined by Bain Capital Life Sciences, Deerfield Management Company and RA Capital Management, among other new investors. Xilio's existing investors, including Atlas Venture, SV Health Investors, Takeda Ventures, RiverVest Venture Partners, and MRL Ventures Fund, also participated in the financing.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about